The NAD+ IV drip has become one of the fastest-growing offerings in the American wellness clinic market. In major cities, a single full-dose session runs between $500 and $1,500. The protocol requires 2 to 4 hours of clinic time, a medical intake screening, and a nurse on-site for the duration of the infusion. Monthly maintenance schedules put the realistic annual cost between $6,000 and $18,000, paid entirely out of pocket. Insurance does not cover it.

The premise behind the drip is, on the surface, straightforward. NAD+ declines with age. Intravenous delivery bypasses the digestive system and puts the molecule directly into the bloodstream, achieving what clinics describe as near-100 percent bioavailability. Direct delivery equals more NAD+ reaching your cells. Simple logic.

That logic is more complicated than the clinics let on.

What "Bioavailability" Actually Measures

When IV clinics describe 100 percent bioavailability, they are referring to what ends up in your bloodstream. That is a pharmacokinetic measurement, not a cellular one. Getting a molecule into circulation and getting it to work inside your cells are two different events.

NAD+ carries a negative charge and cannot freely cross cell membranes on its own. It requires active transport. Research does show that cells can take up extracellular NAD+ through specific channels — but the mechanism is still not fully characterized, and the efficiency varies by cell type. What pharmacokinetic research has documented is that intravenously delivered NAD+ disappears from plasma rapidly, largely within the first two hours of infusion. Whether that means it entered cells or was broken down into metabolites first is a question the clinical record has not cleanly answered.

When IV NAD+ is broken down outside cells, it converts into smaller compounds — NMN, then NR — which cells can then absorb through their own transporters. In other words, the route to intracellular NAD+ elevation may be roughly the same whether you start with IV NAD+ or an oral precursor. The IV drip's assumed advantage over oral supplementation is less certain than the marketing suggests.

This partly explains why many patients experience what clinics call the "NAD flush" during infusion: transient chest tightness, warmth spreading through the chest, nausea, flushing, and dizziness managed by slowing the drip rate. These are documented, common side effects. Not dangerous in a supervised setting. But notable for a molecule that, when functioning normally, stays inside your cells.

The question researchers have been asking is not whether IV NAD+ raises blood levels. It does. The question is whether IV delivery meaningfully outperforms a well-dosed oral precursor for the outcomes most people actually care about — energy, aerobic performance, and long-term cellular function. That data, from IV delivery specifically, is sparse. Most supporting evidence for NAD+ IV therapy comes from observational reports and clinic-generated data. Randomized, double-blind, placebo-controlled trials on IV NAD+ remain very limited.

The oral NMN research has taken a different path.

What the Controlled Trials on Oral NMN Show

In January 2026, researchers at Nestlé Health Science published the first rigorous head-to-head comparison of three NAD+ precursors in Nature Metabolism. In 65 healthy adults, both oral NMN and NR at 1,000 mg/day approximately doubled circulating NAD+ levels after 14 days of supplementation — a sustained elevation, not a temporary spike. Neither had a statistically significant edge over the other. Both also modulated gut bacteria in ways that increased short-chain fatty acid concentrations, compounds associated with a stronger gut barrier and reduced systemic inflammation. Importantly, the study suggests this gut-microbiome conversion to nicotinic acid is part of how oral precursors raise NAD+ — the biology is more involved than any single transporter story.

That doubling effect on circulating NAD+ is consistent with the broader trial record. A Japanese placebo-controlled, randomized, double-blind trial found that oral NMN supplementation significantly elevated NAD+ levels in whole blood in healthy older men after 12 weeks at 250 mg/day. A multicenter trial confirmed dose-dependent NAD+ increases in middle-aged adults at 300, 600, and 900 mg/day. Multiple independent trials conducted between 2020 and 2024 have confirmed that oral NMN raises blood NAD+ in a dose-dependent manner with no significant adverse effects reported.

The Performance Data

The most relevant trial for physically active adults was published in the Journal of the International Society of Sports Nutrition in July 2021. In a 6-week randomized, double-blind, placebo-controlled study on 48 recreationally trained runners (aged 27–50), the 600 mg and 1,200 mg daily NMN groups showed measurable improvements in oxygen uptake (VO2), percentage of maximum oxygen uptake (VO2max%), and power at ventilatory thresholds compared to placebo. The 300 mg group showed no significant benefit.

Two things are worth being straight about. First, the study found no significant difference in absolute VO2max — the headline aerobic capacity metric — between groups. The improvements were in oxygen utilization efficiency and ventilatory thresholds, which matter for endurance performance but are more specific than "increased VO2max." Second, the study population was 83% male. The improvements are real and meaningful for active people. But research specifically in women over 40 remains limited, and the results should not be extrapolated without that caveat.

There is no equivalent published, randomized controlled trial showing comparable aerobic performance outcomes from an IV NAD+ protocol. That is a statement about what the controlled evidence record currently contains, not a claim that IV therapy cannot produce similar effects.

The full trial is available at pmc.ncbi.nlm.nih.gov/articles/PMC8265078.

The Honest Case For IV Therapy

Fairness requires saying when intravenous delivery has a legitimate clinical rationale.

For acute scenarios — severe depletion, significant cognitive decline, or recovery from a medical event — the speed of IV delivery is a genuine advantage. Oral NMN builds NAD+ levels over days and weeks. IV can saturate plasma within hours. For certain clinical applications, that speed matters.

The side effect profile is also manageable with proper oversight. Chest tightness, nausea, and flushing during infusion are common but transient, typically resolved by slowing the drip rate. In a reputable clinic with a qualified nurse present, these are not dangerous events.

What IV therapy lacks is a controlled clinical evidence base showing superior outcomes — for sustained NAD+ restoration in a healthy, active adult — compared to a well-dosed oral precursor. For that use case, the cost structure is dramatically different and the trial evidence points elsewhere.

What This Means For Someone Who Trains

If you are an active person over 40, the relevant question is not which delivery method looks more clinical. It is which method has controlled evidence for the outcomes you are trying to achieve: better oxygen efficiency during training, faster recovery, and sustained cellular energy over time.

The published data on improved aerobic function exists for oral NMN at 600 mg/day. The published data on sustained blood NAD+ elevation exists for oral NMN across multiple independent trials. The cost for a daily 600 mg oral NMN protocol is a fraction of a single IV session.

That is the comparison.

About Omre NMN + Resveratrol

Omre's formula was built around the clinical dosing threshold from the runner trial. Each serving delivers 600 mg of NMN, combined with trans-resveratrol — which activates the sirtuin longevity pathway that elevated NAD+ supports — and BioPerine, a standardized black pepper extract shown to enhance absorption of both compounds.

The formula contains no fillers, no proprietary blends obscuring actual doses.

Purity matters here for a specific reason. Independent lab testing of NMN supplements sold commercially has found significant variance between labeled and actual NMN content across brands. Given that the data shows a clear threshold effect beginning at 600 mg, any product delivering less than labeled is functionally under-dosed. Omre's NMN is independently third-party tested and verified at over 90% purity, manufactured in a GMP-certified facility in the United States.

The dose on the label is the dose in the capsule. Confirmed by an external lab, not by the company.

From People Who Actually Train

None of these reviewers describe an overnight change. They describe a gradual, consistent shift in how their body responds to effort — which is exactly what the controlled trials on NAD+ restoration would predict.

If you have been considering NAD+ IV therapy, or have tried it and wondered whether the outcome justified the cost, the oral NMN clinical data is worth reviewing before your next booking.

Omre NMN + Resveratrol is available at the clinically studied 600 mg daily dose. Subscriptions ship free and are cancel-anytime.

The runner trial is at pmc.ncbi.nlm.nih.gov/articles/PMC8265078. The January 2026 direct NAD+ precursor comparison (Christen et al.) is published in Nature Metabolism and indexed on PubMed under PMID 41540253. Both are freely accessible.